Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/18486
Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain
WOS ID: 000719526500001
Embase PUI: L2014205171
StatisticsItem usage statistics
MetadataShow Dublin Core item record
Document typeresearch article
CitationMontaño JJ, Barceló A, Franch P, Galceran J, Ameijide A, Pons J, et al. Prostate cancer survival by risk and other prognostic factors in mallorca, spain. Int J Environ Res Public Health. 2021;18(21).
Studies about the survival of patients with prostate cancer by stage or risk of progression are scarce. The aims of this study were (1) to determine the cause-specific survival by risk in prostate cancer patients in Mallorca diagnosed in the period 2006-2011; (2) to identify the factors that explain and predict the likelihood of survival and the risk of dying from this type of cancer; and (3) to determine the distribution of prostate cancer by risk in the patients in Mallorca diagnosed in the period 2006-2011. Incident prostate cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. We collected age; date and method of diagnosis; date of follow-up or death; T, N, M and stage according to the TNM 7th edition; Gleason score; prostate-specific antigen (PSA); histology according to the International Classification of Diseases for Oncology (ICD-O) 3rd edition, comorbidities and treatments. We calculated risk in four categories: low, medium, high and very high. The end point of follow-up was 31 December 2014. Multiple imputation (MI) was performed to estimate cases with unknown risk. We identified 2921 cases. Five years after diagnosis, survival after MI was 89% globally, and was 100% for low-risk cases, 96% for medium risk, 93% for high risk and 69% for very-high-risk cases. Cases with histology other than adenocarcinoma, with high (and especially very high) risk, as well as with systemic, mixed and observation/unspecified treatments had worse prognoses.
Estadificación de Neoplasias
Antígeno Prostático Específico
Neoplasias de la Próstata
This item appears in following Docusalut collectionsInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica
Consejería de Salud y Consumo de las Islas Baleares - CSC > Comunicación científica